to asthmatic hyperresponsiveness (4). Accordingly, inhibition of TMEM16A is considered a potential therapeutic target for asthma, other chronic obstructive lung diseases, and PAH.

Dr. Danahay and colleagues have mentioned their unpublished observations about the lack of any bronchospasm during the inhalation of the nebulized ETX001 in a conscious sheep model. However, inhaled drugs such as nitric oxide have strong pulmonary vasoactive effects when they come into close contact with the precapillary vessels. Some inhaled drugs such as iloprost may also be taken up into the systemic circulation where they come into contact with all the organs (5). Therefore, inhaled medications are not completely restricted to the airways.

In addition, in patients independent of CFTR genotype, activation of TMEM16A by denufosol failed to demonstrate any benefit to patients with CF. In a multicenter, randomized, parallel group, double-blind, placebo-controlled trial, the aerosol induced a cough or coughing in more than half of the patients. This adverse effect could be associated with additional mucus production but also with airway obstruction (6).

The proposed activation of TMEM16A as a druggable target in patients with CF poses a number of difficult questions. Enhancement of TMEM16A activity represents an option to improve chloride channel function in CF; however, it also bears risks for clinical complications such as bronchial obstruction, pulmonary hypertension, and disturbances in gut motility. Therefore, any prospective clinical trial should pay special attention to such potential adverse effects. ■

Author disclosures are available with the text of this letter at www.atsjournals.org.

Andrea Olschewski, M.D.*
Medical University of Graz
Graz, Austria

Chandran Nagaraj, Ph.D.
Ludwig Boltzmann Institute for Lung Vascular Research
Graz, Austria

Diana Zabini, Ph.D.
Medical University of Graz
Graz, Austria

Bence M. Nagy, Ph.D.
Ludwig Boltzmann Institute for Lung Vascular Research
Graz, Austria

Grazyna Kwapiszewska, Ph.D.
Horst Olschewski, M.D.
Medical University of Graz
Graz, Austria

and

Ludwig Boltzmann Institute for Lung Vascular Research
Graz, Austria

ORCID IDs: 0000-0002-8189-3634 (A.O.); 0000-0003-3825-8587 (G.K.); 0000-0002-2834-7466 (H.O.).

*Corresponding author (e-mail: andrea.olschewski@medunigraz.at).

References

1. Danahay HL, Lilley S, Fox R, Charlton H, Sabater J, Button B, et al. TMEM16A potentiation: a novel therapeutic approach for the treatment of cystic fibrosis. Am J Respir Crit Care Med 2020;201:946-954.

2. Oh U, Jung J. Cellular functions of TMEM16/anoctamin. Pflugers Arch 2016;468:443-453.

3. Papp R, Nagaraj C, Zabini D, Nagy BM, Lengyel M, Skofic Maurer D, et al. Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic pulmonary arterial hypertension. Eur Respir J 2019;53:1800965.

4. Wang P, Zhao W, Sun J, Tao T, Chen X, Zheng YY, et al. Inflammatory mediators mediate airway smooth muscle contraction through a G protein-coupled receptor-transmembrane protein 16A-voltage-dependent Ca2+ channel axis and contribute to bronchial hyperresponsiveness in asthma. J Allergy Clin Immunol 2018;141:1259–1268.e11.

5. Olschewski H, Simonneau G, Gallié N, Higenbottam T, Naeije R, Rubin LJ, et al.; Aerosolized Iloprost Randomized Study Group. Iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-329.

6. Ratjen F, Durham T, Navratil T, Schaberg A, Accurso FJ, Wainwright C, et al.; TIGER-2 Study Investigator Group. Long term effects of denufosol tetrasodium in patients with cystic fibrosis. J Cyst Fibros 2012;11:539-549.

Copyright © 2020 by the American Thoracic Society

Reply to Olschewski et al.

From the Authors:

Though we appreciate Dr. Olschewski and colleagues’ perspectives on the potential for unwanted effects of increasing the activity of TMEM16A, it should be noted that this is based on studies in which the channel has either been genetically ablated or inhibited with low-potency nonselective blockers. Although these studies provide some guidance around TMEM16A function, an understanding of the effects of positive channel modulation requires potent and selective pharmacological modulators that enhance TMEM16A activity. Through the identification and careful preclinical characterization of TMEM16A potentiators such as ETX001, we have been able to address the potential safety implications of increasing the activity of the channel in addition to developing a deeper understanding of the potential therapeutic benefit (1). Contrary to the concerns outlined by Dr. Olschewski and colleagues, we have recently reported that ETX001 has no effect on airway or vascular smooth muscle function as well as no effect on either airway goblet cell formation or function (2). The local instillation of ETX001 into the airways of rats showed no effects on lung function and did not affect airway smooth muscle tone in isolated human bronchi. Importantly, ETX001 did not affect vascular smooth muscle contraction using freshly isolated human pulmonary artery preparations where compound exposure levels were constant and far in excess of the effective concentration required to give 50% of the maximal response for the channel (2). In addition, ETX001 has been designed to have a short

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/). For commercial usage and reprints, please contact Diane Gern (dgern@thoracic.org).

Originally Published in Press as DOI: 10.1164/rcrn.202004-1214LE on May 28, 2020
systemic half-life to further limit any potential for systemic adverse effects.

The apparent inconsistency between the previously published data and pharmacological data generated using potent and selective TMEM16A potentiators may reflect 1) the imperfect translation of genetically manipulated models, 2) the limitations of using nonselective pharmacological inhibitors to characterize ion channel function, and 3) concluding that positive modulation will deliver the opposite phenotype to inhibition. For example, data reported from pulmonary arterial hypertension models using a Tmem16a knockout and supported by pharmacological studies using the nonselective TMEM16A blocker benzomorphone failed to translate into clinical efficacy (3). In this study, a paradoxical increase in mean pulmonary artery pressure was reported in benzomorphone-treated patients with pulmonary arterial hypertension (3). In addition, although some Tmem16a knockout studies have reported a reduction in blood pressure, overexpression of the channel did not cause an increase in pressure (4).

Dr. Olschewski and colleagues correctly note the failure of the inhaled P2Y2 agonist, denufosol, to demonstrate clinical benefit in patients with cystic fibrosis. The reasons for this are likely multifactorial and may include poor pulmonary pharmacokinetics, rapid degradation by ectonucleotidases, potential receptor desensitization, and emptying of intracellular calcium stores (5, 6). It should be noted that contrary to Dr. Olschewski’s letter, cough and sputum production did not differ between the placebo and denufosol-treated cohorts in the TIGER2 (Transport of Ions to Generate Epithelial Rehydration 2) study. In contrast to P2Y2 agonists, which act indirectly through elevation of intracellular calcium, compounds such as ETX001 selectively enhance the activity of TMEM16A in response to physiologically regulated changes in intracellular calcium (1).

ETD002, a first-in-class TMEM16A potentiator, has successfully completed its Investigational New Drug enabling safety studies with clinical studies expected to commence in 2020. As with all drug candidates in clinical development, the potential for adverse events will be carefully monitored. ■

References

1. Danahay HL, Lilley S, Fox R, Charlton H, Sabater J, Button B, et al. TMEM16A potentiation: a novel therapeutic approach for the treatment of cystic fibrosis. Am J Respir Crit Care Med 2020;201:946–954.

2. Danahay H, Fox R, Lilley S, Charlton H, Adley K, Christie L, et al. Potentiating TMEM16A channel function has no effect on airway goblet cells or bronchial and pulmonary vascular smooth muscle function [preprint]. bioRxiv. 2020. Available from: https://www.biorxiv.org/content/10.1101/2020.04.17.046177v1.

3. Papp R, Nagaraj C, Zabini D, Nagy BM, Skofic Maurer D, et al. Targeting TMEM16A to reverse vasocostriction and remodelling in idiopathic pulmonary arterial hypertension. Eur Respir J 2019;53:1800965.

4. Zeng X-L, Sun L, Zheng H-Q, Wang G-L, Du Y-H, Lv X-F, et al. Smooth muscle-specific TMEM16A expression protects against angiotensin II-induced cerebrovascular remodeling via suppressing extracellular matrix deposition. J Mol Cell Cardiol 2019;134:131–143.

5. Moss RB. Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis. J Pediatr 2013;162:676–680.

6. Button B, Okada SF, Frederick CB, Thein WR, Boucher RC. Mechanosensitive ATP release maintains proper mucus hydration of airways. Sci Signal 2013;6:ra46.